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ABSTRACT 
Purpose: To compare overall survival (OS) of patients with unresectable advanced 
hepatocellular carcinoma (HCC) treated with hepatic arterial infusion chemotherapy (HAIC) plus 
sorafenib or sorafenib alone. 
Patients and Methods: In this multicenter, open-label, randomized, phase 3 trial, patients with 
advanced HCC were randomized (1:1) to sorafenib 400 mg BID orally or sorafenib plus HAIC 
(cisplatin 20 mg/m2 on days 1 and 8 and 5-fluorouracil 330 mg/m2 continuously on days 1–5 and 
8–12 of every 28-day cycle via an implanted catheter system). The primary endpoint was OS. 
Key secondary endpoints were time to progression (TTP), progression-free survival (PFS), 
objective response rate (ORR), disease control rate, and safety. 
Results: Of the 205 patients in the intent-to-treat population, 86.3% were male, 87.4% had 
ECOG-PS of 0, 72.2% had macrovascular invasion or extrahepatic spread, and 88.8% had Child-
Pugh A liver function. Median OS was similar in the sorafenib plus HAIC and sorafenib groups 
(11.8 vs. 11.5 months; P=.955), whereas TTP (5.3 vs. 3.5 months; P=.004), PFS (4.8 vs. 3.5 
months; P=.051), and ORR (36.3% vs 17.5%, P=.003) were significantly greater in the combined 
than in the monotherapy group. OS was tended to be longer in patients with main portal vein 
invasion (MPVI) treated with sorafenib plus HAIC than with sorafenib alone (11.4 vs. 6.5 
months; P=.050). Grade 3–4 adverse events more frequent in the sorafenib plus HAIC group 
included anemia (15.9% vs. 5.9%), neutropenia (17.0% vs. 1.0%), and thrombocytopenia (33.0% 
vs. 11.8%). 
Conclusion: The addition of HAIC to sorafenib did not significantly improve OS in patients with 
advanced HCC, but did significantly improve TTP,  and ORR. Combination therapy tended to 
improve OS in HCC patients with MPVI.  
ClinicalTrials.gov Identifier NCT01214343. 
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Introduction 
Although surgical resection and local ablation therapy such as percutaneous ethanol injection and 
percutaneous radiofrequency ablation are considered curative in patients with hepatocellular 
carcinoma (HCC) (1-3), most patients with HCC are not diagnosed until the disease is 
unresectable (4-6).  Locoregional treatments for unresectable HCC include transarterial 
chemoembolization (TACE), systemic chemotherapy, and hepatic arterial infusion chemotherapy 
(HAIC) (7-11).  In HAIC, anticancer drugs are infused directly into the hepatic artery, increasing 
local intratumoral drug concentrations (12). Drugs infused as monotherapy during HAIC include 
cisplatin, with a response rate of 30-40% (13-17). Combination regimens infused during HAIC 
include cisplatin plus 5-fluorouracil (low-dose FP), with response rates ranging from 7-71% (18-
36).  
HAIC with either low-dose FP or another regimen is widely utilized in Japan, Korea, and 
Taiwan. In retrospective comparative cohort studies, HAIC has shown survival benefits when 
compared with historical controls (37). Moreover, HAIC showed better survival than best 
supportive care in the large cohort of Liver Cancer Study Group of Japan after propensity score 
matching (38). Nevertheless, HAIC is not regarded as standard of care, as no prospective 
randomized phase III trials to date have shown survival benefits in patients with advanced HCC.  
A phase II trial in patients with advanced HCC showed better outcomes with single-dose 
cisplatin arterial infusion chemotherapy plus sorafenib than with sorafenib monotherapy (39). 
The arterial infusion technique in that study however, differed completely from continuous 
HAIC with an implanted catheter port system. Thus, prospective trials are needed to assess the 
safety and efficacy of continuous infusion of low-dose FP in patients with advanced HCC.  
Sorafenib is an oral inhibitor of serine/threonine kinases, including those of vascular endothelial 
growth factor receptors (VEGFR)-2 and -3, platelet-derived growth factor receptor (PDGFR)-β, 
and the Flt-3, kit, and Ret gene products (40). Two randomized, placebo-controlled, phase III 
clinical trials showed that sorafenib improved overall survival in patients with unresectable 
advanced HCC (41, 42). Sorafenib has been approved worldwide and has become the standard 
treatment for patients with advanced unresectable HCC. Two retrospective analyses of 
propensity score-matched patients showed that HAIC did not have survival benefits compared 
with sorafenib monotherapy in patients with advanced HCC (43, 44). However, the combination 
of sorafenib and HAIC may have complementary effects in advanced HCC, with sorafenib 
4 
 
prolonging survival through disease stabilization and HAIC shrinking tumors through high 
response rate (45). A phase I/II study showed that sorafenib plus low-dose FP resulted in 
favorable tumor control and a generally manageable safety profile in patients with advanced 
HCC (45).   Combination treatment with sorafenib and HAIC may, therefore, benefit patients 
with advanced HCC more than either treatment alone.  
The SILIUS trial was a multicenter, phase 3 study comparing sorafenib plus low-dose FP with 
sorafenib monotherapy in patients with advanced, unresectable HCC who had progressed to 
TACE failure, portal vein invasion, or extrahepatic spread. 
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Methods 
Description of patients 
This prospective, randomized, open-label, active-controlled, parallel-group study enrolled 
patients with advanced HCC not suitable for resection, local ablation, or TACE. Advanced HCC 
was defined as ≥4 tumors refractory to TACE or tumors with vascular invasion or extrahepatic 
spread (EHS) based on histologic examination of biopsy samples or findings by dynamic CT, 
dynamic MRI, or CT during hepatic arteriography or arterioportography (CTHA/CTAP), 
according to AASLD criteria. 
 
Inclusion criteria 
Patients with advanced HCC were eligible if they were aged ≥20 years, had a life expectancy 
≥12 weeks, and were not candidates for hepatectomy, local ablation therapy, or TACE. All 
patients had an ECOG PS of 0–1, a Child-Pugh score ≤7, and adequate bone marrow, liver, and 
renal function. 
 
Exclusion criteria 
Patients were excluded if they had another previous or current malignancy except for curatively 
treated intraepithelial cervical cancer, basal cell carcinoma, superficial bladder cancer, early 
gastric cancer, or other early cancers with a low risk of recurrence. Also excluded were patients 
with renal failure requiring hemodialysis or peritoneal dialysis; those with congestive heart 
failure, active coronary artery disease, ischemic heart disease, or serious cardiac arrhythmia; 
patients with poorly controlled hypertension, active clinically serious infection (grade ≥3), 
hearing impairment, history of HIV infection, or significant gastrointestinal bleeding within 4 
weeks of study entry; and patients currently taking a CYP3A4 inhibitor. 
All study subjects provided written informed consent. The study protocol was approved by the 
ethics committees of all participating institutions. The trial was registered at Clinical Trials.gov 
under Identifier NCT01214343. 
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Treatment protocol  
Subjects were randomized 1:1 to receive either sorafenib 400 mg bid or sorafenib 400 mg bid 
plus low-dose FP HAIC. Stratification factors for randomization using the minimization method 
included institution; the presence or absence of EHS, macroscopic vascular invasion (MVI; Vp0, 
Vp1-3, or Vp4), where Vp0 through Vp4 indicated no, third branch, second branch (segmental 
invasion), first branch (branch invasion) and main portal vein invasion, respectively, according 
to Liver Cancer Study Group of Japan criteria.  
Patients in the sorafenib plus HAIC group underwent catheter placement in the hepatic artery for 
24-hour continuous delivery of low-dose cisplatin and 5-fluorouracil through a subcutaneously 
implanted port system. The gastroduodenal artery and/or right gastric vein was embolized using 
a metallic coil to avoid drug flowing to the stomach, duodenum or pancreas. The arterial 
catheters were placed in a manner allowing for proper drug distribution throughout the liver, 
with the flow checked by contrast CT through the port or by DSA before starting treatment.  
Treatment was divided into 28-day cycles. All patients in both groups were treated with oral 
sorafenib 400 mg bid on days 1-28. In the HAIC combination therapy group, cisplatin was 
administered at a dose of 20 mg/m2/day on days 1 and 8 and fluorouracil was administered at a 
dose of 330 mg/m2/day on days 1–5 and 8–12 of every 28-day cycle, followed by 2 weeks off. 
The first treatment cycle was started within 28 days of randomization. Treatment with sorafenib 
prior to HAIC was allowed, but patients were required to be off sorafenib for 2 days before and 7 
days after reservoir port placement.  Treatment was continued until patients experienced 
progressive disease (PD), as defined by modified RECIST criteria and confirmed by imaging, or 
worsening of general condition. Treatment was also discontinued for adverse events, death, 
patient request, or if HAIC became technically infeasible. Patients who experienced a complete 
response (CR) were also discontinued. 
Criteria for delaying the start of the next cycle of treatment included neutrophil count ≤1,000/μl, 
platelet count ≤50,000/μl, total bilirubin ≥2 mg/dl, ALT or AST ≥6 times the institutional upper 
limit of normal, serum creatinine ≥1.5 times the institutional upper limit of normal, and amylase 
≥2 times the institutional upper limit of normal. If these criteria were not met, and the start of the 
next cycle delayed for >8 weeks, the patient was discontinued. Sorafenib doses were adjusted, by 
interruption or reduction, in patients who experienced clinically significant hematologic or non-
hematologic toxicities attributed to sorafenib. As warranted, sorafenib doses were reduced 
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stepwise from 400 mg bid to 400 mg once daily to 400 mg every other day to 200 mg every other 
day. Stepwise increases were allowed after resolution of the adverse event. 
HAIC was interrupted in patients who experienced hematologic and non-hematologic toxicities 
attributed to HAIC. Sorafenib treatment was continued if infusions alone were interrupted. 
Infusions were resumed at the same or a lower dose. Two dose reduction levels of HAIC were 
allowed: 20 mg/m2/day cisplatin and 170 mg/m2/day fluoruracil, and 10 mg/m2/day cisplatin and 
170 mg/m2/day fluoruracil. Cisplatin alone was discontinued without reducing fluoruracil dose in 
patients who experienced adverse events caused by renal dysfunction. 
 
Study endpoints 
The primary study endpoint was overall survival (OS), calculated from the date of randomization 
until death from any cause or date of last evaluation. Secondary study endpoints included time to 
progression (TTP), calculated from the date of randomization until diagnosis of progression by 
modified RECIST criteria; progression-free survival (PFS), calculated from the date of 
randomization until diagnosis of tumor progression or death from any cause, whichever was 
sooner; overall response rate (ORR), calculated as the percentage of patients who achieved either 
a complete response (CR), or partial response (PR) to treatment; disease control rate (DCR), 
calculated as the percentage of patients who achieved CR, PR, and stable disease (SD); and 
safety. 
 
Statistical analysis 
Calculation of sample size 
Sample size was based on assumptions that the median OS in patients receiving sorafenib 
monotherapy would be 10 months and that HAIC would improve median OS by 70% (hazard 
ratio [HR] 0.59). Thus, 112 events would be necessary to achieve a power of 80% for a one-
sided α of 0.05 and 1:1 group assignment. The necessary number of events would be observed if 
164 patients were followed for 36 months (enrollment period of 24 months and follow-up period 
of 12 months). Based on a drop-out rate of 15%, target enrollment was set at 190 patients (95 per 
group). 
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Other statistical methods 
Results were reported as mean ± SD, number (%), or median (95% confidence interval [CI]), as 
warranted, and compared by Student’s t-tests or Chi-squared tests. Survival outcomes were 
calculated using the Kaplan-Meier method and compared by log-rank tests. Outcomes in the two 
groups were reported as HR and 95% CI. All statistical analyses were performed using SPSS 
version 23 statistical software, with a p-value <0.05 defined as statistically significant. 
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Results 
Patient population  
A total of 206 patients were randomized, 103 to treatment with sorafenib monotherapy and 103 
to sorafenib plus HAIC combination therapy. One patient who was randomized to sorafenib plus 
HAIC withdrew after randomization, leaving 205 patients in the intent-to-treat (ITT) population. 
Fifteen patients, one in the sorafenib group and 14 in the sorafenib plus HAIC group, were not 
treated, leaving 190 patients in the safety population (Figure 1). 
The two groups were generally well matched (Table 1). Mean ages of patients in the ITT 
population randomized to sorafenib and sorafenib plus HAIC were 68.1 ± 9.1 years and 66.7 ± 
10.2 years, respectively, and 85.4% and 87.3%, respectively, were male. There were also no 
significant differences between the two groups in terms of Child-Pugh grade, disease etiology, 
BCLC stage, and the presence of EHS and MVI. 
Although the mean duration of sorafenib treatment was slightly longer in the sorafenib plus 
HAIC treatment group, the median duration was slightly longer in the sorafenib monotherapy 
group (Supplementary Table 1). Mean and median relative sorafenib dose intensities were 
greater in the group treated with sorafenib alone. The mean and median numbers of HAIC cycles 
in the sorafenib plus HAIC group were 4.0 and 2.0, respectively. 
  
Efficacy outcomes 
Kaplan-Meier analysis showed that OS, the primary endpoint, was similar in the two treatment 
groups (Figure 2A). Median OS was 11.5 months (95% CI, 8.2–14.8 months) in patients treated 
with sorafenib monotherapy and 11.8 months (95% CI, 9.1–14.5 months) in patients treated with 
sorafenib plus HAIC (HR 1.009; 95% CI, 0.743–1.371, P=.955).  
Differences in OS were observed when patients were stratified by MVI (Figure 3). Median OS 
in patients with Vp1-3 (branch-segmental portal vein invasion) was longer with sorafenib 
monotherapy (14.4 months; 95% CI, 9.3–19.5 months) than with sorafenib plus HAIC (12.6 
months; 95% CI, 4.3–20.9 months), although the difference was not statistically significant (HR 
1.367; 95% CI, 0.829–2.255, P=.218). In contrast, median OS in patients with Vp4 (main portal 
vein invasion: MPVI) tended to be longer in those treated with sorafenib plus HAIC (11.4 
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months; 95% CI, 7.0–15.9 months) than in those treated with sorafenib alone (6.5 months; 95% 
CI, 4.5–8.4 months; HR 0.493; 95% CI, 0.240–1.014, P=.050). Forest plot analysis of factors 
associated with OS also showed that OS was greater in patients with Child-Pugh score 6 treated 
with sorafenib monotherapy than with sorafenib plus HAIC (Figure 4). However, sorafenib plus 
HAIC resulted in longer OS in patients with MPVI and in those with Child-Pugh score 7 than did 
sorafenib alone. 
Analysis of secondary outcomes showed TTP was significantly longer and PFS tended to be 
longer in patients treated with sorafenib plus HAIC than in patients treated with sorafenib alone 
(Figure 2B, C). ORR was significantly greater in patients treated with sorafenib plus HAIC than 
in those treated with sorafenib monotherapy (36.3% vs 17.5%, P=.003). DCR rates were similar 
(72.8% vs 64.7%, P=.230; Table 2). Patients in each arm were stratified by whether they 
achieved CR/PR or SD/PD. Kaplan-Meier analysis showed that OS was significantly greater in 
the CR/PR than in the SD/PD subgroups (Supplementary Figure 1A, B). Moreover, a 
comparison of patients who achieved CR/PR showed that OS was longer for those in the 
sorafenib monotherapy group than in the sorafenib plus HAIC group, although the difference 
was not statistically significant (Supplementary Figure 1C). 
 
Safety outcomes 
Adverse event rates were generally similar in the two groups (Table 3). However, rates of all 
grade and grades 3/4 reductions in neutrophil and platelet counts were significantly higher in the 
sorafenib plus HAIC than in the sorafenib monotherapy group. In contrast, rates of all-grade 
alopecia, hoarseness, diarrhea, and increased ALT were significantly higher in the sorafenib 
monotherapy than in the sorafenib plus HAIC group, whereas rates of all-grade nausea, 
vomiting, and decreased white blood cell counts were significantly higher in the sorafenib plus 
HAIC group. Adverse events associated with the implanted catheter system were observed only 
in the sorafenib plus HAIC group.  
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Discussion 
Systemic chemotherapy agents have shown little efficacy in patients with advanced HCC (46, 
47). In contrast, the phase III Sorafenib Hepatocellular Carcinoma Assessment Randomized 
Protocol (SHARP) and Asia-Pacific trials showed that sorafenib significantly prolonged OS in 
patients with advanced HCC, resulting in a significant advance in the treatment of this disease 
(41, 42). Other new agents tested in a first-line setting, including sunitinib, brivanib, and 
linifanib, and combinations of sorafenib with other agents, including the anti-angiogenic agent 
erlotinib and the cytotoxic agent doxorubicin (48-52), failed to show better survival benefit than 
sorafenib alone.  
A phase I/II study in patients with advanced HCC found that sorafenib plus low-dose FP resulted 
in favorable tumor control and a generally manageable safety profile (45). These findings 
suggested that the combination of sorafenib and low-dose FP HAIC would improve OS in 
patients with advanced HCC. However, the current phase III SILIUS trial found that, compared 
with sorafenib monotherapy, this combination did not improve OS in patients with advanced 
unresectable HCC.  
In SILIUS, combination therapy with sorafenib plus low-dose FP HAIC resulted in significantly 
higher TTP and ORR than did sorafenib monotherapy, suggesting that HAIC may have an 
additive anti-cancer effect on sorafenib. This is similar to findings reported previously in 
retrospective cohort studies of patients with advanced HCC (18-38). In a large, nationwide 
cohort study of patients with advanced HCC who were treated with low-dose FP HAIC, median 
OS was significantly longer in responders to low-dose FP HAIC (CR+PR) than in nonresponders  
(SD+PD) (25.8 months vs. 6.0 months, respectively) (38), with similar findings reported in 
another study (37). This phase III SILIUS trial also demonstrated survival benefits in responders 
(CR+PR) to combination therapy, through high response rate and slower TTP, compared with n 
responders to sorafenib alone. The finding that ORR was significantly higher with the use of 
combination therapy than with sorafenib monotherapy indicated that a much higher fraction of 
the enrichable patient population experienced survival benefits from combination therapy than 
from sorafenib alone.  
The present study also found that combination therapy tended to improve OS and 1- and 2-year 
survival rates in HCC patients with MPVI (Vp4) when compared with sorafenib monotherapy, a 
finding consistent with previous reports (18-21, 38). An analysis of 57,445 patients with 
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advanced HCC prospectively registered in the nationwide database of the Liver Cancer Study 
Group of Japan from 2000 through 2005 compared 476 patients who received low-dose FP 
HAIC using a subcutaneous infusion port with 1,466 patients who received best supportive care 
(48). After propensity score matching, median OS was significantly longer in the 189 patients 
with MPVI who received low-dose FP HAIC than in the 189 who did not (7.9 months vs. 3.1 
months). In comparison, the average OS in patients with MPVI was found to be <3 months (53-
56). In SILIUS, the median OS in patients treated with low-dose FP HAIC plus sorafenib was 
11.4 months compared with 6.5 months in patients treated with sorafenib monotherapy. 
Overall, these findings suggest that, compared with sorafenib alone, the combination of low-dose 
FP HAIC and sorafenib may benefit selected patients with advanced HCC. These include older 
patients, those with MPVI (Vp4), patients with Child-Pugh scores of 7 and responders to this 
combination therapy. No unexpected AEs were reported. 
The major limitation of this study was the small numbers of patients in the various subgroups, 
making it difficult to determine the statistical significance of outcomes in these groups. 
Additional studies with larger numbers of patients are required to determine whether sorafenib 
plus low-dose FP HAIC has advantages over sorafenib alone in patients with advanced HCC, 
especially in patients with MPVI. 
In conclusion, low-dose FP HAIC plus sorafenib did not improve OS in patients with advanced 
HCC and MVI and/or EHS compared with sorafenib monotherapy.  However, combination 
treatment did increase ORR and TTP, suggesting that this combination may benefit some 
selected patients. These results are consistent with those of retrospective cohort studies, which 
found that response rate was higher in patients treated with low-dose FP HAIC plus sorafenib 
compared with sorafenib alone, with the higher percentage of responders to combination therapy 
resulting in longer survival in responder subgroups. Furthermore, patients with MPVI may 
benefit from low-dose FP HAIC combination therapy. Further large-scale trials are warranted.  
 
Acknowledgment 
This research was supported by the grant of Japanese Ministry of Health, Labour and Welfare. 
 
13 
 
References 
 
1. Donadon M, Solbiati L, Dawson L, Barry A, Sapisochin G, Greig PD, Shiina S, et al. Hepatocellular 
Carcinoma: The Role of Interventional Oncology. Liver Cancer 2016;6:34-43. 
2. Lanza E, Donadon M, Poretti D, Pedicini V, Tramarin M, Roncalli M, Rhee H, et al. Transarterial 
Therapies for Hepatocellular Carcinoma. Liver Cancer 2017;6:27-33. 
3. Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, et al. Survival 
Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan. Liver Cancer 
2016;5:190-197. 
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917. 
5. Geschwind JF, Gholam PM, Goldenberg A, Mantry P, Martin RC, Piperdi B, Zigmont E, et al. Use of 
Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular 
Carcinoma: US Regional Analysis of the GIDEON Registry. Liver Cancer 2016;5:37-46. 
6. Chow PK, Choo SP, Ng DC, Lo RH, Wang ML, Toh HC, Tai DW, et al. National Cancer Centre 
Singapore Consensus Guidelines for Hepatocellular Carcinoma. Liver Cancer 2016;5:97-106. 
7. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With 
Hepatocellular Carcinoma. Gastroenterology 2016;150:835-853. 
8. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, et al. Asia-Pacific clinical practice 
guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-370. 
9. Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, et al. Evidence-based 
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update 
(3rd JSH-HCC Guidelines). Hepatol Res 2015;45:123-127. 
10. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, et al. JSH Consensus-Based 
Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver 
Cancer Study Group of Japan. Liver Cancer 2014;3:458-468. 
11. Kudo M, Trevisani F, Abou-Alfa GK, Rimassa L. Hepatocellular Carcinoma: Therapeutic Guidelines 
and Medical Treatment. Liver Cancer 2017;6:16-26. 
12. Moriguchi M, Aramaki T, Nishiofuku H, Sato R, Asakura K, Yamaguchi K, Tanaka T, et al. Sorafenib 
versus Hepatic Arterial Infusion Chemotherapy as Initial Treatment for Hepatocellular Carcinoma with 
Advanced Portal Vein Tumor Thrombosis. Liver Cancer 2017;6:275-286. 
13. Court WS, Order SE, Siegel JA, Johnson E, DeNittis AS, Principato R, Martz K, et al. Remission and 
survival following monthly intraarterial cisplatinum in nonresectable hepatoma. Cancer Invest 
2002;20:613-625. 
14. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic 
chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999;46:1122-1125. 
15. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion 
of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 
2008;38:474-483. 
16. Iwasa S, Ikeda M, Okusaka T, Ueno H, Morizane C, Nakachi K, Mitsunaga S, et al. Transcatheter 
arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular 
carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol 2011;41:770-775. 
17. Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular 
carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma. Cancer Chemother Pharmacol 
1987;19:183-189. 
18. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, et al. Hepatic arterial 
infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: 
analysis of 48 cases. Cancer 2002;95:588-595. 
19. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular 
carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer 1997;79:1890-1896. 
14 
 
20. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, Ito K. Hepatic arterial infusion of 
5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus 
of the portal vein. J Surg Oncol 2002;80:143-148. 
21. Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, Liu HT, et al. Hepatic arterial infusion 
chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 
2003;9:2666-2670. 
22. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, et al. Hepatic arterial 
infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for 
multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999;6:587-591. 
23. Tanioka H, Tsuji A, Morita S, Horimi T, Takamatsu M, Shirasaka T, Mizushima T, et al. Combination 
chemotherapy with continuous 5-fluorouracil and low-dose cisplatin infusion for advanced hepatocellular 
carcinoma. Anticancer Res 2003;23:1891-1897. 
24. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. The efficacy of 
continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe 
advanced hepatocellular carcinoma. Oncology 1995;52:295-299. 
25. Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, et al. Hepatic arterial infusion 
chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. 
Oncology 2010;78 Suppl 1:148-153. 
26. Saeki I, Yamasaki T, Tanabe N, Iwamoto T, Matsumoto T, Urata Y, Hidaka I, et al. A new therapeutic 
assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion 
chemotherapy. PLoS One 2015;10:e0126649. 
27. Oh MJ, Lee HJ, Lee SH. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced 
hepatocellular carcinoma as first-line therapy. Clin Mol Hepatol 2013;19:288-299. 
28. Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, Im HU, et al. A randomized comparative study 
of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced 
hepatocellular carcinoma. Cancer Chemother Pharmacol 2010;65:373-382. 
29. Tsai WL, Lai KH, Liang HL, Hsu PI, Chan HH, Chen WC, Yu HC, et al. Hepatic arterial infusion 
chemotherapy for patients with huge unresectable hepatocellular carcinoma. PLoS One 2014;9:e92784. 
30. Lin CP, Yu HC, Cheng JS, Lai KH, Lo GH, Hsu PI, Lin CK, et al. Clinical effects of intra-arterial infusion 
chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced 
hepatocellular carcinoma. J Chin Med Assoc 2004;67:602-610. 
31. Song MJ, Bae SH, Chun HJ, Choi JY, Yoon SK, Park JY, Han KH, et al. A randomized study of cisplatin 
and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular 
carcinoma. Cancer Chemother Pharmacol 2015;75:739-746. 
32. Ma MC, Chen YY, Li SH, Cheng YF, Wang CC, Chiu TJ, Pei SN, et al. Intra-arterial chemotherapy with 
doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. ScientificWorldJournal 
2014;2014:160138. 
33. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, et al. Combined therapy consisting 
of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with 
major portal vein thrombosis or distant metastasis. Cancer 2000;88:1986-1991. 
34. Uka K, Aikata H, Takaki S, Miki D, Kawaoka T, Jeong SC, Takahashi S, et al. Pretreatment predictor 
of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination 
therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 2007;42:845-853. 
35. Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, Tomimaru Y, et al. Long-
term outcome of combined interferon-alpha and 5-fluorouracil treatment for advanced hepatocellular 
carcinoma with major portal vein thrombosis. Oncology 2011;80:63-69. 
36. Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, Mizukoshi E, et al. 
Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil 
plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 
2011;81:281-290. 
15 
 
37. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, et al. Combination therapy of 
intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with 
portal venous invasion. Cancer 2006;106:1990-1997. 
38. Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, et al. Effect of hepatic 
arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in 
the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer 2013;109:1904-1907. 
39. Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, et al. Sorafenib plus 
hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular 
carcinoma: randomized phase II trial. Ann Oncol 2016;27:2090-2096. 
40. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, et al. BAY 43-9006 exhibits 
broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine 
kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109. 
41. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in 
advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390. 
42. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al. Efficacy and safety of sorafenib in 
patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, 
double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. 
43. Fukubayashi K, Tanaka M, Izumi K, Watanabe T, Fujie S, Kawasaki T, Yoshimaru Y, et al. Evaluation 
of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular 
carcinoma: a comparative study using the propensity score matching method. Cancer Med 2015;4:1214-
1223. 
44. Shiozawa K, Watanabe M, Ikehara T, Kogame M, Matsui T, Okano N, Kikuchi Y, et al. Comparison 
of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A 
Propensity Score Matching Study. Hepatogastroenterology 2014;61:885-891. 
45. Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, et al. Phase I/II Study of 
Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-
Fluorouracil. Liver Cancer 2015;4:263-273. 
46. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, et al. A randomized phase III study of 
doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination 
chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538. 
47. Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for 
hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg 
Oncol 2008;15:1008-1014. 
48. Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, Kudo M, et al. Linifanib versus Sorafenib in 
patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 
2015;33:172-179. 
49. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, et al. Sunitinib versus sorafenib in 
advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013;31:4067-4075. 
50. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, et al. Brivanib versus sorafenib 
as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the 
randomized phase III BRISK-FL study. J Clin Oncol 2013;31:3517-3524. 
51. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, et al. SEARCH: a phase III, 
randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced 
hepatocellular carcinoma. J Clin Oncol 2015;33:559-566. 
52. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, et al. Doxorubicin 
plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized 
trial. Jama 2010;304:2154-2160. 
53. Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, et al. Transarterial 
chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main 
portal vein and may improve the overall survival. Radiology 2011;258:627-634. 
16 
 
54. Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial 
chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein 
obstruction. A prospective controlled study. Cancer 1997;79:2087-2094. 
55. Yoon JH, Kim HC, Chung JW, Yoon JH, Jae HJ, Park JH. CT findings of completely regressed 
hepatocellular carcinoma with main portal vein tumor thrombosis after transcatheter arterial 
chemoembolization. Korean J Radiol 2010;11:69-74. 
56. Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal 
vein thrombosis. Clin Mol Hepatol 2015;21:115-121. 
 
 
  
17 
 
Table 1. Baseline demographic and clinical characteristics of the intent-to-treat (efficacy) population 
 Sorafenib (n=103) Sorafenib + HAIC (n=102) 
Age, yrs, mean ± SD 68.1 ± 9.1 66.7 ± 10.2 
Sex, n (%)   
     Male 88 (85.4) 89 (87.3) 
     Female 15 (14.6) 13 (12.7) 
Child-Pugh grade, n (%)   
     A 92 (89.3) 90 (88.2) 
     B 11 (10.7) 12 (11.8) 
Etiology, n (%)   
     Hepatitis B 22 (21.4) 26 (25.5) 
     Hepatitis C 46 (44.7) 47 (46.1) 
BCLC Stage, n (%)   
     B 27 (26.2) 32 (31.4) 
     C 76 (73.8) 70 (68.6) 
MVI present, n (%) 64 (62.1) 58 (56.9) 
EHS present, n (%) 26 (25.2) 27 (26.5) 
MVI/EHS present, n (%) 75 (72.8) 73 (71.6) 
AFP (ng/dl) 195.0 440.5 
DCP (mAU/ml) 1487.0 2780.5 
AFP-L3 (ng/dl) 24.6 21.6 
Abbreviations: AFP, alfa-fetoprotein; AFP-L3, L3 fraction of AFP; BCLC, Barcelona clinic liver cancer; 
DCP, des-γ–carboxyprotein; EHS; extra hepatic spread; MVI, macrovascular invasion. 
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Table 2. Summary of best response by mRECIST criteria in the randomized population. 
 Sorafenib  
(n=103)  
Sorafenib + HAIC  
(n=102)  
P-value 
Best response, n (%)   <0.001 
   Complete response (CR) 2 (1.9)   8 (7.8)  
   Partial response (PR) 16 (15.5) 29 (28.4)  
   Stable disease (SD) 57 (55.3) 29 (28.4)  
   Progressive disease (PD) 21 (20.4) 16 (15.7)  
   Not evaluable 7 (6.8) 20 (19.6)  
ORR (CR + PR), n (%) 18 (17.5) 37 (36.3) 0.003 
DCR (CR + PR + SD), n (%) 75 (72.8) 66 (64.7) 0.230 
Abbreviations:  CR, complete response; DCR, disease control rate; ORR, overall response rate; PD, 
progressive disease; PR, partial response; SD, stable disease.  
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Table 3. All-grade treatment-emergent adverse events with frequency >15% in either group and 
corresponding grade 3/4 adverse events 
 Sorafenib, % 
(n=102) 
Sorafenib + HAIC, % 
 (n=88) 
P-value 
 All-Grade Grade 3/4 All-Grade Grade 3/4 All-Grade Grade 3/4 
Elevated AST 96.1 29.4 94.3 27.3 0.841 0.744 
Elevated ALT 87.3 14.7 72.7 13.6 0.015 0.833 
Thrombocytopenia 80.4 11.8 89.8 33.0 0.036 <0.001 
Anemia 77.5 5.9 85.2 15.9 0.071 0.025 
Hypertension 76.5 25.5 76.1 25.0 0.912 0.938 
Elevated lipase 65.7 34.3 61.4 28.4 0.318 0.383 
Elevated bilirubin 64.7 11.8 62.5 8.0 0.843 0.383 
Hand-foot skin reaction  58.8 13.7 48.9 9.1 0.197 0.319 
Elevated serum amylase 56.9 10.8 48.9 11.4 0.184 0.899 
Malaise 52.9 0.0 46.6 0.0 0.430 NA 
Anorexia 52.9 5.9 55.7 12.5 0.630 0.111 
Diarrhea 48.0 9.8 33.0 3.4 0.041 0.082 
Decreased WBC count 48.0 4.9 67.0 12.5 0.006 0.060 
Elevated INR 48.0 0.0 43.2 0.0 0.604 NA 
Neutropenia 41.2 1.0 67.0 17.0 <0.001 <0.001 
Fatigue 39.2 7.8 30.7 9.1 0.243 0.757 
Weight loss 32.4 1.0 37.5 0.0 0.774 0.352 
Hoarseness 32.4 1.0 15.9 0.0 0.010 0.352 
Alopecia 25.5 0.0 8.0 0.0 0.002 NA 
Fever 24.5 2.9 22.7 0.0 0.811 0.105 
Nausea 16.7 2.0 35.2 4.5 0.003 0.310 
Vomiting 6.9 1.0 19.3 3.4 0.009 0.245 
Implanted catheter 
system trouble 
0.0 0.0 18.2 12.5 NA NA 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international 
normalized ratio.  
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Figure 1. Patient disposition during the study.  
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Figure 2. Kaplan-Meier analysis of (A) overall survival, (B) time to progression, and (C) 
progression-free survival in patients treated with sorafenib alone and sorafenib plus HAIC. 
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Figure 3. Kaplan-Meier analysis of overall survival in patients treated with sorafenib alone and 
sorafenib plus HAIC and stratified by MVI. (A) Vp1–3 and (B) Vp4. 
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Figure 4. Forest plot of factors associated with overall survival in patients treated with sorafenib 
alone and sorafenib plus HAIC. 
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Supplementary Table 1. Dose intensities of sorafenib and number of HAIC cycles in the safety 
population. 
 Sorafenib  
(n=102)  
Sorafenib + HAIC 
(n=88)  
Duration of sorafenib treatment, weeks   
   Mean ± SD 23.9 ± 29.0   25.0 ± 31.9   
   Median (range) 14.4 (159.3) 13.6 (216.0) 
Relative sorafenib dose intensity, %   
   Mean ± SD 60.0 ± 25.6   53.7 ± 26.6   
   Median  55.6 (100.0) 53.1 (100.0) 
Total number of HAIC cycles (1 cycle = 
28 days) 
 (n=85) 
   Mean ± SD  4.0 ± 4.0   
   Median (range)  2.0 (19.0) 
 
  
25 
 
Supplementary Figure 1. Kaplan-Meier analysis of overall survival in patients stratified by tumor 
response. (A, B) OS was significantly longer in patients who achieved CR+PR than in those who 
achieved SD+PD in response to sorafenib alone (A) and sorafenib plus HAIC (B). (C) OS was 
similar in patients who achieved CR+PR in response to sorafenib alone and sorafenib plus 
HAIC. 
 
